SCHEMBL10326271

SCHEMBL10326271

N=C(S)NCCc1cccc(CCNC(=N)S)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 1/20 0.45
MTNR1B P49286 1/20 0.45
NOS1 P29475 2/20 0.44
CYP2D6 P10635 1/20 0.44
NOS3 P29474 1/20 0.44
NOS2 P35228 1/20 0.44
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
ALDH1A1 P00352 3/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
HPGD P15428 1/20 0.41
SPR P35270 1/20 0.41
HDAC3 O15379 2/20 0.40
HDAC1 Q13547 2/20 0.40
HDAC2 Q92769 2/20 0.40
HDAC10 Q969S8 2/20 0.40
HDAC11 Q96DB2 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14914554 0.83 ST14 (0.47) CYP2D6LMNASMN1; SMN2NPC1RAB9A
SCHEMBL7871359 0.80 MTNR1A (0.49) MTNR1AMTNR1BNOS1CYP2D6NOS3
SCHEMBL2811627 0.79 ALDH1A1 (0.52) NOS1CYP2D6NOS3NOS2LMNA
Bromide SCHEMBL2811699 0.78 ALDH1A1 (0.50) NOS1CYP2D6NOS3NOS2LMNA
SCHEMBL10591303 0.72 KDM4E (0.66) MTNR1AMTNR1BLMNASMN1; SMN2ALDH1A1
SCHEMBL22827196 0.71 HDAC3 (0.52) LMNASMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL3926078 0.71 DRD2 (0.55) NOS1CYP2D6NOS3NOS2LMNA
SCHEMBL3926060 0.69 TAAR1 (0.57) NOS1NOS3LMNAALDH1A1TAAR1
SCHEMBL21556969 0.69 TAAR1 (0.57) NOS1CYP2D6NOS3NOS2NPC1
SCHEMBL15139083 0.69 F10 (0.47) NOS1CYP2D6NOS3NOS2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9090589-B2 Specific nNOS inhibitors for the therapy and prevention of human melanoma NORTHWESTERN UNIVERSITY (US) 2015-07-28 US disclosed
US-20140147920-A1 Specific nNOS Inhibitors for the Therapy and Prevention of Human Melanoma THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-29 US disclosed
US-8642282-B2 Inhibitors of nitric oxide synthase for treatment of melanoma NORTHWESTERN UNIVERSITY (US) 2014-02-04 US disclosed
US-20120238016-A1 Specific nNOS Inhibitors for the Therapy And Prevention Of Human Melanoma NORTHWESTERN UNIVERSITY 2012-09-20 US disclosed
WO-2012097121-A2 SPECIFIC NNOS INHIBITORS FOR THE THERAPY AND PREVENTION OF HUMAN MELANOMA NORTHWESTERN UNIVERSITY (US) 2012-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140147920-A1 Specific nNOS Inhibitors for the Therapy and Prevention of Human Melanoma NOS3, NOS1, NOS2 MTNR1A 192/4885MTNR1B 272/4885NOS1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.